Dr. David Horwitz, MD

Dr. David Horwitz, MD  is a physician-scientist and immunologist who is internationally recognized for his work in T-cell biology, especially related to immune regulation. He has served as Professor of Medicine and Molecular Immunology and Chief of Division of Rheumatology and Immunology at the University of Southern California  (USC) Keck School of Medicine for 27 years.  He served as a Professor of Medicine at the University of Virginia, Charlottesville, VA before joining USC.  Dr. Horwitz is a Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations.  He is a Master of the American College of Rheumatology.

As a pioneering researcher and physician-scientist, Dr. Horwitz has characterized many abnormalities of the immune system in patients with systemic lupus erythematosus. He was the first to recognize the role of IL-2 and TGF-β in the development of regulatory/suppressor T-cells, an observation that is now immunological dogma. The primary objective of his internationally recognized academic career has been to utilize our increasing knowledge of the immune system to develop a therapy that is more effective, yet safer than the agents now used to treat systemic lupus erythematosus, other autoimmune diseases, graft versus host disease, and allograft rejection. Dr. Horwitz holds several patents on methods for treating immunologic diseases.  He published more than 100 research articles in high impact medical-scientific journals.  He is Co-Founder of Toralgen, Inc. and Chief Executive Officer of General Nanotherapeutics, LLC.  Dr. Horwitz has been developing orally delivered bile acid nanoformulations of small molecules and biologics for treatment of autoimmune diseases.  He will provide expert guidance regarding the potential application of the oral nanoformulation platform for the delivery of the Oncotelic RNA therapeutic as a “nano pill” in pancreas cancer patients.